Interleukin-6 is constitutively produced by human CTL clones and is required to maintain their cytolytic function

doi:10.1016/0008-8749(91)90128-X

Cellular Immunology

Volume 138, Issue 1, November 1991, Pages 11-23

https://doi.org/10.1016/0008-8749(91)90128-X Get rights and content

Abstract

Maturation of cytolytic T lymphocytes from nonlytic precursors requires cytokines in addition to IL2. Interleukin-6 is the principal cytokine that cooperates with IL2 in the induction of CTL differentiation from murine and human thymocyte precursors. However, a cytotoxic differentiation factor (CDF) role of IL6 for mature T cells is challenged by data indicating that IL2 alone is sufficient for CTL generation. The aim of this study was to identify a model system in which IL6 acted as a CDF for human peripheral T cells. We noted that IL6 was endogenously produced by CTL clones in the course of their expansion with APC, lectin, and IL2. The majority of several hundred T-cell clones, both CD4+ and CD8+, produced IL6 in response to relatively high doses of IL2. Other experiments that compared the cytolytic function of CTL clones cultured in the presence of IL6 with that of the same clones cultured in the absence of IL6 demonstrated that IL6 contributes to the cytolytic ability of the majority of human CTL clones. Our data suggest that IL6 acts in an autocrine fashion to support CTL differentiation in human T-cell clones.

References (43)

C. Cernetti et al.
Cell. Immunol
(1987)
A. Weiss
D.H. Raulet et al.
Nature (London)
(1982)
H. Wagner et al.
J. Exp. Med
(1982)
O. Kanagawa
J. Immunol
(1982)
D.N. Männel et al.
J. Immunol
(1983)
R.D. Garman et al.
J. Immunol
(1983)
J.H. Finke et al.
J. Immunol
(1983)
W. Falk et al.
J. Immunol
(1983)
M.K. Gately et al.
J. Immunol
(1986)

T. Kishimoto et al.

J. Takai et al.

J. Immunol

(1986)

Y. Takai et al.

J. Immunol

(1988)

C. Cernetti et al.

M. Okada et al.

J. Immunol

(1988)

J.E. Ming et al.

J. Mol. Cell. Immunol

(1989)

F. Erard et al.

J. Immunol

(1985)

E. Maraskovsky et al.

J. Immunol

(1989)

M.B. Widmer et al.

Nature (London)

(1987)

G. Trenn et al.

J. Immunol

(1988)

M.B. Widmer et al.

J. Exp. Med

(1987)

Cited by (27)

Mn-Si-based nanoparticles-enhanced inhibitory effect on tumor growth and metastasis in photo-immunotherapy
2023, Colloids and Surfaces B: Biointerfaces
The anticancer effect of phototherapy has been limited by some factors, including the easy degradation of photo agents, the complex tumor microenvironment, and the limited immune activation capacity, which impedes its efficiency in inhibiting tumor growth and tumor metastasis. Herein, Mn-doped mesoporous silica nanoparticles were synthesized to load the photo agent of IR 780, which were further coated with Mn (IMM). Notably, the combination of IMM and an 808 nm laser irradiation simultaneously inhibited the growth of primary tumors and distant untreated tumors in a bilateral animal model, which could be attributed to the protection of IMM to IR 780, the regulation functions to the tumor microenvironment, as well as the enhanced immune activation capacity. This work highlighted an alternative strategy for enhancing the inhibitory effect on both tumor growth and tumor metastasis in the combinational anticancer therapy of phototherapy and immunotherapy (photo-immunotherapy).
3,3′-Diindolylmethane stimulates murine immune function in vitro and in vivo
2008, Journal of Nutritional Biochemistry
3,3′-Diindolylmethane (DIM), a major condensation product of indole-3-carbinol, exhibits chemopreventive properties in animal models of cancer. Recent studies have shown that DIM stimulates interferon-gamma (IFN-γ) production and potentiates the IFN-γ signaling pathway in human breast cancer cells via a mechanism that includes increased expression of the IFN-γ receptor. The goal of this study was to test the hypothesis that DIM modulates the murine immune function. Specifically, the effects of DIM were evaluated in a panel of murine immune function tests that included splenocyte proliferation, reactive oxygen species (ROS) generation, cytokine production and resistance to viral infection. DIM was found to induce proliferation of splenocytes as well as augment mitogen- and interleukin (IL)-2-induced splenocyte proliferation. DIM also stimulated the production of ROS by murine peritoneal macrophage cultures. Oral administration of DIM, but not intraperitoneal injection, induced elevation of serum cytokines in mice, including IL-6, granulocyte colony-stimulating factor (G-CSF), IL-12 and IFN-γ. Finally, in a model of enteric virus infection, oral DIM administration to mice enhanced both clearance of reovirus from the GI tract and the subsequent mucosal IgA response. Thus, DIM is a potent stimulator of immune function. This property might contribute to the cancer inhibitory effects of this indole.
Cotransfection of DC with TLR4 and MART-1 RNA induces MART-1-specific responses
2005, Journal of Surgical Research
Cotransfection of dendritic cells (DC) with MART-1 and constitutively active TLR4 (caTLR4) RNA enhances the maturation of DC.
Immature DC were cotransfected with RNA constructs encoding MART-1 and caTLR4, and CTL responses were analyzed.
Cotransfection of DC with MART-1 + caTLR4 enhanced the expression of CD80 and CD83 surface markers and increased the secretion of cytokines IL-6, IL-12, and TNFα. Neither the native nor the A27L-modified MART-1 RNA could induce significant DC maturation or cytokine secretion. More importantly, DC cotransfected with caTLR4 + MART-1 RNA induced MART-1-specific CTL responses of a higher magnitude than DC transfected with either the native or A27L MART-1 RNA. When the MART-1 RNA-transfected DC were treated with DC-maturing cytokines, the induced CTL were less frequent and less lytic than those induced with MART-1 + caTLR4. A 2- to 100-fold increase in MART-1 tetramer⁺ cells and 2- to 10-fold increases in IFNγ secretion and cytotoxicity were seen in CTL induced with MART-1 + caTLR4 compared to CTL induced with either MART-1 or A27L RNA. CTL induced with the mixed RNA displayed high percentages of CD8⁺ cells coexpressing CD45RA, CD56, and 2B4 antigens. Transfection with caTLR4 alone induced DC maturation, but did not induce lytic CTL, suggesting that CTL responses were induced solely by MART-1 epitopes.
caTLR4 increases the CTL-inducing capacity of DC generating a lytic response specific for the accompanying antigen. These results demonstrate the possibility of enhancing the immunogenicity of the native MART-1 and other RNA derived from weakly immunogenic tumors in DC-based immunotherapy.
Increase of interleukin 6 and decrease of interleukin 2 production during the ageing process are influenced by the health status
1998, Mechanisms of Ageing and Development
The ageing process is accompanied by the disregulation of interleukin 2 (IL2) and interleukin 6 (IL6) production. In our paper, we asked whether the age between 60 and 70 years is a turning point for the disregulation of both IL2 and IL6 production. Fifty volunteers 60–70 years old, 25 aged 36–59, and 50 of 20–35 years old were enrolled into the study. Their health status was graded according to the criteria of the Senieur Protocol (SP) as `healthy' and `almost-healthy'. The cytokines level was determined in the sera of the volunteers. Moreover, the spontaneous release of IL6 by peripheral blood mononuclear cells (PBMC) and the activity of the IL6 gene in non-stimulated PBMC were also analysed. Cytokine levels were measured by biological assays, mRNA for IL6 was detected by RT-PCR method. The results showed that the production of IL2 is not disregulated in the `healthy' people until the age of 60–70. People not fulfilling all SP criteria are characterised by a lower level of IL2 in the sera. The overproduction of IL6 into the sera and supernatants from non-stimulated PBMC and PBL as well as the activation of IL6 gene start between the ages 36 and 59 and is more pronounced in the `almost-healthy'.
IL-6: Insights into novel biological activities
1997, Clinical Immunology and Immunopathology
Interleukin 6 in diseases: Cause or cure?
1996, Immunopharmacology

View all citing articles on Scopus

^☆: Supported by a grant from the Italian Association for Cancer Research (AIRC) to A.V.

View full text

Interleukin-6 is constitutively produced by human CTL clones and is required to maintain their cytolytic function☆

Abstract

Cell. Immunol

Nature (London)

J. Exp. Med

J. Immunol

J. Immunol

J. Immunol

J. Immunol

J. Immunol

J. Immunol

J. Immunol

J. Immunol

J. Immunol

J. Mol. Cell. Immunol

J. Immunol

J. Immunol

Nature (London)

J. Immunol

J. Exp. Med